Stewart Merrill H, Jahangir Eiman, Polin Nichole M
John Ochsner Heart and Vascular Institute, University of Queensland School of Medicine, 1514 Jefferson Highway, New Orleans, LA, 70121, USA.
Division of Cardiology, Kaiser Permanente Northern California, 401 Bicentennial Drive, Santa Rosa, CA, 95403, USA.
Curr Treat Options Cardiovasc Med. 2017 Jul;19(7):53. doi: 10.1007/s11936-017-0550-6.
Cardiac valvular disease as consequence of radiation and chemotherapy during treatment for malignancy is growing in its awareness. While the overwhelming emphasis in this population has been on the monitoring and preservation of left ventricular systolic function, we are now developing a greater appreciation for the plethora of cardiac sequelae beyond this basic model. To this end many institutions across the country have developed cardio-oncology programs, which are collaborative practices between oncologists and cardiologists in order to minimize a patient's cardiovascular risk while allowing them to receive the necessary treatment for their cancer. These programs also help to recognize early nuanced treatment complications such as valvular heart disease, and provide consultation for the most appropriate course of action. In this article we will discuss the etiology, prevalence, diagnosis, and current treatment options of valvular heart disease as the result of chemotherapy and radiation.
作为恶性肿瘤治疗期间放疗和化疗后果的心脏瓣膜病正日益受到关注。虽然该人群一直以来主要强调对左心室收缩功能的监测和保护，但我们现在越来越认识到在这个基本模型之外还有大量的心脏后遗症。为此，全国许多机构都开展了心脏肿瘤学项目，这是肿瘤学家和心脏病学家之间的合作实践，目的是在让患者接受必要的癌症治疗的同时，尽量降低其心血管风险。这些项目还有助于识别早期细微的治疗并发症，如瓣膜性心脏病，并为最合适的行动方案提供咨询。在本文中，我们将讨论化疗和放疗导致的瓣膜性心脏病的病因、患病率、诊断及当前的治疗选择。
